Conference
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A)
Authors
Sonpavde G; Sternberg CN; Lee J-L; de Miranda PAP; Lima AR; Sarkeshik M; Hotte SJ
Volume
38
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
February 20, 2020
Name of conference
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
CA, San Francisco
Conference start date
February 13, 2020
Conference end date
February 15, 2020
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
6
ISSN
0732-183X